Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul;10(7):e955-e956.
doi: 10.1016/S2214-109X(22)00217-0.

Statin use in low-income and middle-income countries - Authors' reply

David Flood  1 , Maja E Marcus  2 , Silver K Bahendeka  3 , Sahar Saeedi Moghaddam  4 , Corine Houehanou  5 , Sebastian Vollmer  2 , Mark D Huffman  6
Affiliations
Comment

Statin use in low-income and middle-income countries - Authors' reply

David Flood et al. Lancet Glob Health. 2022 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

MDH has patents pending for heart failure polypills. MDH has received meeting or travel support from the American Heart Association and World Heart Federation. MDH has an appointment at The George Institute for Global Health, which has a patent and licence, and has received investment funding with the intent to commercialise fixed-dose combination therapy through its social enterprise business called George Medicines. DF reports grant funding within the past 3 years from a Pilot and Feasibility Grant funded by the Michigan Center for Diabetes Translational Research (NIH Grant P30-DK092926) and a grant from the Swinmurn Foundation to implement a sustainable diabetes clinic in Guatemala. DF also reports volunteer affiliations with Wuqu’ Kawoq and GlucoSalud, outside of the submitted work. During the course of the study, DF received research fellowship funding from National Clinician Scholars Program at the University of Michigan Institute for Healthcare Policy and Innovation. All other authors declare no competing interests.

Comment on

References

    1. Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews. JAMA Cardiol 2016; 1(3): 341–9. - PMC - PubMed
    1. Rahimi K, Bidel Z, Nazarzadeh M, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. The Lancet 2021; 397(10285): 1625–36. - PMC - PubMed
    1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267–78. - PubMed
    1. Kaptoge S, Pennells L, De Bacquer D, et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. The Lancet Global Health 2019; 7(10): e1332–e45. - PMC - PubMed
    1. Basu S, Flood D, Geldsetzer P, et al. Estimated effect of increased diagnosis, treatment, and control of diabetes and its associated cardiovascular risk factors among low-income and middle-income countries: a microsimulation model. Lancet Glob Health 2021; 9(11): e1539–e52. - PMC - PubMed

Substances